| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30006414 | HIV | ENSG00000129484.14 | protein_coding | PARP2 | No | No | 10038 | Q9UGN5 |
| TVIS30035882 | HIV | ENSG00000129484.14 | protein_coding | PARP2 | No | No | 10038 | Q9UGN5 |
| TVIS30035883 | HIV | ENSG00000129484.14 | protein_coding | PARP2 | No | No | 10038 | Q9UGN5 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | PARP2 |
|---|---|
| DrugBank ID | DB09074 |
| Drug Name | Olaparib |
| Target ID | BE0003798 |
| UniProt ID | Q9UGN5 |
| Regulation Type | inhibitor |
| PubMed IDs | 25981132; 30069770 |
| Citations | Verhagen CV, de Haan R, Hageman F, Oostendorp TP, Carli AL, O'Connor MJ, Jonkers J, Verheij M, van den Brekel MW, Vens C: Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother Oncol. 2015 Sep;116(3):358-65. doi: 10.1016/j.radonc.2015.03.028. Epub 2015 May 13.@@Bochum S, Berger S, Martens UM: Olaparib. Recent Results Cancer Res. 2018;211:217-233. doi: 10.1007/978-3-319-91442-8_15. |
| Groups | Approved |
| Direct Classification | Phthalazinones |
| SMILES | FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1 |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL521686 |
